PT  - JOURNAL ARTICLE
AU  - Alexei Vazquez
TI  - Multi-type branching and graph product theory of infectious disease outbreaks
AID  - 10.1101/2020.10.09.20210252
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.09.20210252
4099  - http://medrxiv.org/content/early/2020/10/13/2020.10.09.20210252.short
4100  - http://medrxiv.org/content/early/2020/10/13/2020.10.09.20210252.full
AB  - The heterogeneity of human populations is a major challenge to mathematical descriptions of infectious disease outbreaks. Numerical simulations are therefore deployed to account for the many factors influencing the disease spreading dynamics. Yet, the results from numerical simulations are often as complicated as the reality, leaving us with a sense of confusion about how the different factors account for the simulation results. Here, using a multi-type branching together with a graph tensor product approach, I derive a single equation for the effective reproductive number of an infectious disease outbreak. Using this equation I deconvolute the impact of crowd management, contact heterogeneity, testing, vaccination, mask use and smartphone tracing app use. This equation can be used to gain a basic understanding of infectious disease outbreaks and their simulations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Cancer Research UK C596/A21140Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA